E
EiraBio utilizes synthetic biology and directed evolution platforms to discover and optimize precision antibodies against historically inaccessible multi-pass membrane proteins. The company's scalable yeast-based technology enables the targeting of complex targets like GPCRs, ion channels, and solute transporters. This approach unlocks new therapeutic opportunities for diseases with high unmet medical needs.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Eira Bio utilizes synthetic biology and directed evolution platforms to discover and optimize novel antibodies against challenging, historically inaccessible multi-pass membrane proteins. Their scalable yeast-based technology enables the precise targeting of complex receptors like GPCRs and ion channels. This approach unlocks new therapeutic opportunities for diseases with high unmet medical needs.